APHERESIS COLLECTION OF MOBILIZED HEMATOPOIETIC STEM CELLS FROM PERIPHERAL BLOOD IN HEALTY DONORS ? 15 YEARS OF EXPERIENCE
(Abstract release date: 05/19/16)
EHA Library. Grubovikj Rastvorceva R. 06/09/16; 134752; PB1852
Dr. Rada Grubovikj Rastvorceva
Contributions
Contributions
Abstract
Abstract: PB1852
Type: Publication Only
Background
Mobilized hematopoietic peripheral blood stem cell (PBSC) has been widely used for allogeneic transplantation in different hematologic malignancies. Optimal donor and recipient outcomes require maximized stem cell collection efficiency.
Aims
The aim of our study is to present our experience of 15 years in collecting of PBSC in healthy donors.
Methods
This is a retrospective study performed in the Institute for Transfusion Medicine of Republic of Macedonia and University Hematology Hospital for period from January 2001 till December 2015. All donors were HLA typed and matched; they were fully informed on the donation procedure and signed an informed consent for donation. Minimum dose required to ensure successful and sustained engraftment was 2x10^6/kg CD34+ cells and 2x10^8/kg mono-nucleated cells (MNC). PBSC harvesting was performed with continuous flow cell separator Baxter C53000 and COBE Spectra using conventional-volume apheresis processing the 2 – 2.5 total blood volumes per apheresis. A femoral catheter was used for harvesting and Acid Citrate Dextrose formula A is used for anticoagulation. Recombinant human granulocyte colony-stimulating factor (G-CSF) is used to mobilize PBPC for collection. Harvesting of PBSC is usually performed after 4 to 5 days of G-CSF subcutaneous administration at a dose of 10 μg/kg body weight.
Results
All the donors were siblings of the patients treated at the University Hematology Hospital. There were 126 apheresis procedures performed in 74 healthy sibling donors. There were 48 males and 26 females, aged 19-55. The single procedure usually took 3-4 hours and the volume of collected stem cells was 50-220 ml. The needed number of MNC and CD34+ cells was successfully collected by 1.7 apheresis (range 1-2). There were 9 ABO incompatible donors. Procedures for mobilization and collection of PBPC from healthy donors are generally well tolerated. The only adverse effects of the apheresis procedure were bone pain as reaction of G-CSF and numbness of the extremities as reaction of ACD-A (hypocalcemia), which occur rarely and were very mild. The collected PBSC were used in allogeneic stem cell transplantation in patients with: acute myeloid leukemia – 61.3%, acute lymphoblastic leukemia – 17.7%, chronic myeloid leukemia – 9%, myeloproliferative disorders – 4.1%, severe aplastic anemia – 2.7%, non-Hodgkin lymphoma – 2.7%, chronic lymphoblastic leukemia - 1.3%, Hodgkin disease – 1.3% and multiple myeloma – 1.3%.
Conclusion
The apheresis collection of PBSC in healthy donors is an effective and safe procedure. We are developing a National Stem Cell Donors Registry as a part of Bone Marrow Donors Worldwide. In that way we hope we will help widen the world network of stem cell donors and enlarge the possibility for each patient to find the right match.
Session topic: E-poster
Keyword(s): Apheresis, Peripheral blood stem cell, Stem cell collection
Type: Publication Only
Background
Mobilized hematopoietic peripheral blood stem cell (PBSC) has been widely used for allogeneic transplantation in different hematologic malignancies. Optimal donor and recipient outcomes require maximized stem cell collection efficiency.
Aims
The aim of our study is to present our experience of 15 years in collecting of PBSC in healthy donors.
Methods
This is a retrospective study performed in the Institute for Transfusion Medicine of Republic of Macedonia and University Hematology Hospital for period from January 2001 till December 2015. All donors were HLA typed and matched; they were fully informed on the donation procedure and signed an informed consent for donation. Minimum dose required to ensure successful and sustained engraftment was 2x10^6/kg CD34+ cells and 2x10^8/kg mono-nucleated cells (MNC). PBSC harvesting was performed with continuous flow cell separator Baxter C53000 and COBE Spectra using conventional-volume apheresis processing the 2 – 2.5 total blood volumes per apheresis. A femoral catheter was used for harvesting and Acid Citrate Dextrose formula A is used for anticoagulation. Recombinant human granulocyte colony-stimulating factor (G-CSF) is used to mobilize PBPC for collection. Harvesting of PBSC is usually performed after 4 to 5 days of G-CSF subcutaneous administration at a dose of 10 μg/kg body weight.
Results
All the donors were siblings of the patients treated at the University Hematology Hospital. There were 126 apheresis procedures performed in 74 healthy sibling donors. There were 48 males and 26 females, aged 19-55. The single procedure usually took 3-4 hours and the volume of collected stem cells was 50-220 ml. The needed number of MNC and CD34+ cells was successfully collected by 1.7 apheresis (range 1-2). There were 9 ABO incompatible donors. Procedures for mobilization and collection of PBPC from healthy donors are generally well tolerated. The only adverse effects of the apheresis procedure were bone pain as reaction of G-CSF and numbness of the extremities as reaction of ACD-A (hypocalcemia), which occur rarely and were very mild. The collected PBSC were used in allogeneic stem cell transplantation in patients with: acute myeloid leukemia – 61.3%, acute lymphoblastic leukemia – 17.7%, chronic myeloid leukemia – 9%, myeloproliferative disorders – 4.1%, severe aplastic anemia – 2.7%, non-Hodgkin lymphoma – 2.7%, chronic lymphoblastic leukemia - 1.3%, Hodgkin disease – 1.3% and multiple myeloma – 1.3%.
Conclusion
The apheresis collection of PBSC in healthy donors is an effective and safe procedure. We are developing a National Stem Cell Donors Registry as a part of Bone Marrow Donors Worldwide. In that way we hope we will help widen the world network of stem cell donors and enlarge the possibility for each patient to find the right match.
Session topic: E-poster
Keyword(s): Apheresis, Peripheral blood stem cell, Stem cell collection
Abstract: PB1852
Type: Publication Only
Background
Mobilized hematopoietic peripheral blood stem cell (PBSC) has been widely used for allogeneic transplantation in different hematologic malignancies. Optimal donor and recipient outcomes require maximized stem cell collection efficiency.
Aims
The aim of our study is to present our experience of 15 years in collecting of PBSC in healthy donors.
Methods
This is a retrospective study performed in the Institute for Transfusion Medicine of Republic of Macedonia and University Hematology Hospital for period from January 2001 till December 2015. All donors were HLA typed and matched; they were fully informed on the donation procedure and signed an informed consent for donation. Minimum dose required to ensure successful and sustained engraftment was 2x10^6/kg CD34+ cells and 2x10^8/kg mono-nucleated cells (MNC). PBSC harvesting was performed with continuous flow cell separator Baxter C53000 and COBE Spectra using conventional-volume apheresis processing the 2 – 2.5 total blood volumes per apheresis. A femoral catheter was used for harvesting and Acid Citrate Dextrose formula A is used for anticoagulation. Recombinant human granulocyte colony-stimulating factor (G-CSF) is used to mobilize PBPC for collection. Harvesting of PBSC is usually performed after 4 to 5 days of G-CSF subcutaneous administration at a dose of 10 μg/kg body weight.
Results
All the donors were siblings of the patients treated at the University Hematology Hospital. There were 126 apheresis procedures performed in 74 healthy sibling donors. There were 48 males and 26 females, aged 19-55. The single procedure usually took 3-4 hours and the volume of collected stem cells was 50-220 ml. The needed number of MNC and CD34+ cells was successfully collected by 1.7 apheresis (range 1-2). There were 9 ABO incompatible donors. Procedures for mobilization and collection of PBPC from healthy donors are generally well tolerated. The only adverse effects of the apheresis procedure were bone pain as reaction of G-CSF and numbness of the extremities as reaction of ACD-A (hypocalcemia), which occur rarely and were very mild. The collected PBSC were used in allogeneic stem cell transplantation in patients with: acute myeloid leukemia – 61.3%, acute lymphoblastic leukemia – 17.7%, chronic myeloid leukemia – 9%, myeloproliferative disorders – 4.1%, severe aplastic anemia – 2.7%, non-Hodgkin lymphoma – 2.7%, chronic lymphoblastic leukemia - 1.3%, Hodgkin disease – 1.3% and multiple myeloma – 1.3%.
Conclusion
The apheresis collection of PBSC in healthy donors is an effective and safe procedure. We are developing a National Stem Cell Donors Registry as a part of Bone Marrow Donors Worldwide. In that way we hope we will help widen the world network of stem cell donors and enlarge the possibility for each patient to find the right match.
Session topic: E-poster
Keyword(s): Apheresis, Peripheral blood stem cell, Stem cell collection
Type: Publication Only
Background
Mobilized hematopoietic peripheral blood stem cell (PBSC) has been widely used for allogeneic transplantation in different hematologic malignancies. Optimal donor and recipient outcomes require maximized stem cell collection efficiency.
Aims
The aim of our study is to present our experience of 15 years in collecting of PBSC in healthy donors.
Methods
This is a retrospective study performed in the Institute for Transfusion Medicine of Republic of Macedonia and University Hematology Hospital for period from January 2001 till December 2015. All donors were HLA typed and matched; they were fully informed on the donation procedure and signed an informed consent for donation. Minimum dose required to ensure successful and sustained engraftment was 2x10^6/kg CD34+ cells and 2x10^8/kg mono-nucleated cells (MNC). PBSC harvesting was performed with continuous flow cell separator Baxter C53000 and COBE Spectra using conventional-volume apheresis processing the 2 – 2.5 total blood volumes per apheresis. A femoral catheter was used for harvesting and Acid Citrate Dextrose formula A is used for anticoagulation. Recombinant human granulocyte colony-stimulating factor (G-CSF) is used to mobilize PBPC for collection. Harvesting of PBSC is usually performed after 4 to 5 days of G-CSF subcutaneous administration at a dose of 10 μg/kg body weight.
Results
All the donors were siblings of the patients treated at the University Hematology Hospital. There were 126 apheresis procedures performed in 74 healthy sibling donors. There were 48 males and 26 females, aged 19-55. The single procedure usually took 3-4 hours and the volume of collected stem cells was 50-220 ml. The needed number of MNC and CD34+ cells was successfully collected by 1.7 apheresis (range 1-2). There were 9 ABO incompatible donors. Procedures for mobilization and collection of PBPC from healthy donors are generally well tolerated. The only adverse effects of the apheresis procedure were bone pain as reaction of G-CSF and numbness of the extremities as reaction of ACD-A (hypocalcemia), which occur rarely and were very mild. The collected PBSC were used in allogeneic stem cell transplantation in patients with: acute myeloid leukemia – 61.3%, acute lymphoblastic leukemia – 17.7%, chronic myeloid leukemia – 9%, myeloproliferative disorders – 4.1%, severe aplastic anemia – 2.7%, non-Hodgkin lymphoma – 2.7%, chronic lymphoblastic leukemia - 1.3%, Hodgkin disease – 1.3% and multiple myeloma – 1.3%.
Conclusion
The apheresis collection of PBSC in healthy donors is an effective and safe procedure. We are developing a National Stem Cell Donors Registry as a part of Bone Marrow Donors Worldwide. In that way we hope we will help widen the world network of stem cell donors and enlarge the possibility for each patient to find the right match.
Session topic: E-poster
Keyword(s): Apheresis, Peripheral blood stem cell, Stem cell collection
{{ help_message }}
{{filter}}